Cara Therapeutics, Inc. (CARA): Price and Financial Metrics

Cara Therapeutics, Inc. (CARA)

Today's Latest Price: $14.86 USD

0.93 (6.68%)

Updated Oct 20 4:00pm

Add CARA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

CARA Stock Summary

  • Of note is the ratio of Cara Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 6.43% of US stocks have a lower such ratio.
  • For CARA, its debt to operating expenses ratio is greater than that reported by just 6.3% of US equities we're observing.
  • CARA's price/sales ratio is 27.19; that's higher than the P/S ratio of 93.76% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Cara Therapeutics Inc, a group of peers worth examining would be ANAB, MORF, MGNX, PTGX, and VBLT.
  • Visit CARA's SEC page to see the company's official filings. To visit the company's web site, go to

CARA Stock Price Chart Interactive Chart >

Price chart for CARA

CARA Price/Volume Stats

Current price $14.86 52-week high $26.67
Prev. close $13.93 52-week low $8.88
Day low $14.14 Volume 903,800
Day high $15.23 Avg. volume 489,323
50-day MA $14.76 Dividend yield N/A
200-day MA $15.41 Market Cap 696.74M

Cara Therapeutics, Inc. (CARA) Company Bio

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. The company was founded in 2004 and is based in Shelton, Connecticut.

CARA Latest News Stream

Event/Time News Detail
Loading, please wait...

CARA Latest Social Stream

Loading social stream, please wait...

View Full CARA Social Stream

Latest CARA News From Around the Web

Below are the latest news stories about Cara Therapeutics Inc that investors may wish to consider to help them evaluate CARA as an investment opportunity.

New finance chief at Cara Therapeutics

Cara Therapeutics (CARA) appoints Thomas Reilly as CFO, effective October 1, 2020.He joins Cara from Allergan, now part of AbbVie, where he served as Finance Head for the U.S. General Medicine Commercial Business. Source: Press Release...

Seeking Alpha | October 1, 2020

Choyce Peterson Negotiates 11,685 SF Expansion for Cara Therapeutics Headquarters in Stamford, CT

NORWALK, Conn. , Sept. 21, 2020 /PRNewswire/ -- Choyce Peterson , Inc. ( ), a full-service commercial real estate brokerage and consulting firm, announced that it has successfully concluded negotiations for an 11,685 SF headquarters expansion on behalf of Cara Therapeutics, Inc. ("Cara") at 107 Elm Street in Stamford, CT . Principal John Hannigan and Vice President Adam Cognetta represented Cara during this transaction. … Full story available on

Benzinga | September 21, 2020

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2020 Results - Earnings Call Transcript

Cara Therapeutics, Inc. (CARA) Q2 2020 Earnings Conference Call August 10, 2020 04:30 PM ET Company Participants Jack Hildick-Smith - Stern IR Derek Chalmers - President and CEO Rick Makara - VP and Head, Accounting Conference Call Participants Chris Howerton - Jefferies David Amsellem - Piper Sandler Annabel Samimy -...

SA Transcripts on Seeking Alpha | August 11, 2020

Cara Therapeutics Reports Second Quarter 2020 Financial Results

– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical…

GlobeNewswire | August 10, 2020

Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference

STAMFORD, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and…

GlobeNewswire | August 6, 2020

Read More 'CARA' Stories Here

CARA Price Returns

1-mo 5.02%
3-mo -15.71%
6-mo -6.19%
1-year -23.12%
3-year 19.55%
5-year 2.70%
YTD -7.76%
2019 23.92%
2018 6.21%
2017 31.75%
2016 -44.90%
2015 69.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8122 seconds.